Join
Live feed
·
PRReleasevia Quantisnow
Sensei Biotherapeutics Inc. logo

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

ByQuantisnow·Wall Street's wire, on your screen.
SNSE· Sensei Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNSE (Sensei Biotherapeutics Inc.) and more on Quantisnow.